In line with FDA guidance that clinicians monitor for new or worsening depression, suicidal thoughts, or unusual changes in mood during GLP-1 RA treatment [46], brief psychological screening should be incorporated at baseline and repeated at intervals during treatment at weeks 6, 12, and 24, and then at least every six months
Although preclinical findings have been encouraging in several areas, responses can vary significantly between individuals, and treatment decisions should always be based on a comprehensive medical assessment rather than a single therapy
Through the effective use of high stability-liposomes, it offers a non-invasive alternative that closely mimics the efficiency of intravenous therapy
Most major commercial insurers (Blue Cross Blue Shield, United Healthcare, Aetna, Cigna) have plans that cover GLP-1 for weight loss, but coverage varies by specific plan, employer, and state
Here are some of the most common causes